share_log

HC Wainwright & Co. Maintains Buy on Panbela Therapeutics, Lowers Price Target to $5

Benzinga ·  Apr 2 20:49

HC Wainwright & Co. analyst Joseph Pantginis maintains Panbela Therapeutics (OTC:PBLA) with a Buy and lowers the price target from $16 to $5.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment